Interruption of intermittent hypoxia attenuates the severity of pulmonary fibrosis in male mice
Physiological Reports · 2025-05 · 13 (10)
DOI: 10.14814/phy2.70335 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiological Reports, online erschienen am 22.05.2025. Verfasst von Zakaria Maakoul und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire Hypoxie & Poumon, UMR INSERM U1272, Université Sorbonne Paris-Nord, Bobigny, France. Hauptthemen laut MEDLINE: Hypoxia, Pulmonary Fibrosis, Sleep Apnea, Obstructive, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Legs poix, Chancellerie des Universités de Paris, Sorbonne, Bonus Qualite Recherche Universite Sorbonne Paris Nord.
Abstract (Originalsprache)
Obstructive sleep apnoea ( OSA ) leading to chronic intermittent hypoxia ( CIH ) is a common comorbidity associated with idiopathic pulmonary fibrosis ( IPF ), a progressive fatal disease characterized by adverse lung remodeling and parenchymal stiffening. In the mouse model of lung fibrosis induced by intra‐tracheal instillation ( ITI ) of bleomycin, we have previously shown that CIH exacerbates fibrosis, similar to pre‐exposure to ITI . It has been suggested that correction of OSA and CIH with positive airway pressure may have a beneficial effect on the progression of fibrosis in IPF patients. Therefore, we designed this study to determine the benefits of stopping CIH in mice pre‐exposed to CIH for 3 weeks prior to bleomycin ITI . Interruption of CIH exposure was associated with less diffuse lung fibrosis, reduced ratio of damaged area, alveolar destruction, collagen deposition, and fibrosis score. Interruption of CIH exposure significantly reduced macrophage density in fibrotic areas without significant changes in either lymphocyte or neutrophil density. In conclusion, this study demonstrates that early treatment of OSA ‐associated CIH can limit or reduce the development of severe forms of pulmonary fibrosis associated with a reduction in macrophage infiltrate and supports the beneficial effect of CIH exposure interruption on ongoing fibrosis severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire Hypoxie & Poumon, UMR INSERM U1272, Université Sorbonne Paris-Nord, Bobigny, France.
- Faculté de Médecine, Sorbonne Université, Paris, France.
- Service de Physiologie et d'Explorations Fonctionnelles, Hôpital Avicenne, APHP, Bobigny, France.
- Univ. Grenoble Alpes, INSERM, CEA, UA13 BGE, CNRS, FR2048 ProFI, EDyP Team, Grenoble, France.
ORCID-Profile: Emilie Boncoeur
Förderung
- Legs poix, Chancellerie des Universités de Paris, Sorbonne
- Bonus Qualite Recherche Universite Sorbonne Paris Nord
Zitieren
APA
Maakoul, Z., Yegen, C. H., Marchant, D., Bernaudin, J. F., Planès, C., Voituron, N., & Boncoeur, E. (2025). Interruption of intermittent hypoxia attenuates the severity of pulmonary fibrosis in male mice. Physiological Reports, 13(10). https://doi.org/10.14814/phy2.70335
Vancouver
Maakoul Z, Yegen CH, Marchant D, Bernaudin JF, Planès C, Voituron N, et al. Interruption of intermittent hypoxia attenuates the severity of pulmonary fibrosis in male mice. Physiological Reports. 2025;13(10). doi:10.14814/phy2.70335
BibTeX
@article{Maakoul2025,
author = {Maakoul, Zakaria and Yegen, Celine-Hivda and Marchant, Dominique and Bernaudin, Jean-Francois and Planès, Carole and Voituron, Nicolas and Boncoeur, Emilie},
title = {Interruption of intermittent hypoxia attenuates the severity of pulmonary fibrosis in male mice},
journal = {Physiological Reports},
year = {2025},
volume = {13},
number = {10},
doi = {10.14814/phy2.70335}
}
EUVIMED